User profiles for Sophie L. Stocker

Sophie Stocker

School of Pharmacy, University of Sydney
Verified email at sydney.edu.au
Cited by 3446

Renal transporters in drug development

KM Morrissey, SL Stocker, MB Wittwer… - Annual review of …, 2013 - annualreviews.org
The kidney plays a vital role in the body's defense against potentially toxic xenobiotics and
metabolic waste products through elimination pathways. In particular, secretory transporters …

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol

…, M Hicks, AJ McLachlan, SL Stocker… - Clinical …, 2007 - Springer
Allopurinol is the drug most widely used to lower the blood concentrations of urate and,
therefore, to decrease the number of repeated attacks of gout. Allopurinol is rapidly and …

Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance

…, RB Kim, AS Ray, SL Stocker… - Clinical …, 2018 - Wiley Online Library
This white paper provides updated International Transporter Consortium (ITC) recommendations
on transporters that are important in drug development following the 3 rd ITC workshop. …

[HTML][HTML] Researchers' views on, and experiences with, the requirement to obtain informed consent in research involving human participants: a qualitative study

A Xu, MT Baysari, SL Stocker, LJ Leow, RO Day… - BMC medical …, 2020 - Springer
Background Informed consent is often cited as the “cornerstone” of research ethics. Its intent
is that participants enter research voluntarily, with an understanding of what their …

Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and …

WH Chung, WC Chang, SL Stocker, CG Juo… - Annals of the …, 2015 - ard.bmj.com
Objective Allopurinol, an antihyperuricaemic agent, is one of the common causes of life-threatening
severe cutaneous adverse reactions (SCAR), including drug rash with eosinophilia …

The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin

SL Stocker, KM Morrissey, SW Yee… - Clinical …, 2013 - Wiley Online Library
Interindividual variation in response to metformin, first‐line therapy for type 2 diabetes, is
substantial. Given that transporters are determinants of metformin pharmacokinetics, we …

[HTML][HTML] Clinical pharmacokinetics in kidney disease: fundamental principles

TN Lea-Henry, JE Carland, SL Stocker… - Clinical journal of the …, 2018 - journals.lww.com
Kidney disease is an increasingly common comorbidity that alters the pharmacokinetics of
many drugs. Prescribing to patients with kidney disease requires knowledge about the drug, …

Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin

EC Chen, X Liang, SW Yee, EG Geier, SL Stocker… - Molecular …, 2015 - ASPET
Metformin, the most widely prescribed antidiabetic drug, requires transporters to enter
tissues involved in its pharmacologic action, including liver, kidney, and peripheral tissues. …

[HTML][HTML] Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens

…, J Sevastos, JE Carland, SL Stocker… - Clinical Journal of the …, 2018 - journals.lww.com
A change in pharmacokinetics can alter drug exposure and predispose the patient to either
over-or underdosing, potentially resulting in adverse drug reactions or therapeutic failure. …

A model averaging/selection approach improves the predictive performance of model‐informed precision dosing: vancomycin as a case study

DW Uster, SL Stocker, JE Carland… - Clinical …, 2021 - Wiley Online Library
Many important drugs exhibit substantial variability in pharmacokinetics and pharmacodynamics
leading to a loss of the desired clinical outcomes or significant adverse effects. …